Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models

Therapies in non-alcoholic steatohepatitis (NASH)

(2017) Abdul M. Oseini et al.   LIVER INTERNATIONAL

Effect of modulation of PPAR-γ activity on Kupffer cells M1/M2 polarization in the development of non-alcoholic fatty liver disease

(2017) Wenjing Luo et al.   Scientific Reports

Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD

(2016) Alexandra Montagner et al.   GUT

Non-alcoholic fatty liver disease and diabetes

(2016) Jonathan M. Hazlehurst et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Saroglitazar for the treatment of dyslipidemia in diabetic patients

(2015) Shashank R Joshi   EXPERT OPINION ON PHARMACOTHERAPY

Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease

(2015) Michal Pawlak et al.   JOURNAL OF HEPATOLOGY

Role of Mitochondria in Nonalcoholic Fatty Liver Disease

(2014) Fatiha Nassir et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis

(2013) Masahiko Matsumoto et al.   INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY

Multiple Hits, Including Oxidative Stress, as Pathogenesis and Treatment Target in Non-Alcoholic Steatohepatitis (NASH)

(2013) Akinobu Takaki et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

PPARγ signaling and metabolism: the good, the bad and the future

(2013) Maryam Ahmadian et al.   NATURE MEDICINE

GW501516-activated PPARβ/δ promotes liver fibrosis via p38-JNK MAPK-induced hepatic stellate cell proliferation

(2012) Radina Kostadinova et al.   Cell and Bioscience

Telmisartan improves nonalcoholic steatohepatitis in medaka (Oryzias latipes) by reducing macrophage infiltration and fat accumulation

(2011) Shinya Kuwashiro et al.   CELL AND TISSUE RESEARCH

Prevalence of and Risk Factors for Hepatic Steatosis and Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: the Edinburgh Type 2 Diabetes Study

(2011) R. M. Williamson et al.   DIABETES CARE

Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites

(2010) Brent A. Neuschwander-Tetri   HEPATOLOGY

Role of Peroxisome Proliferator-activated Receptor δ/β in Hepatic Metabolic Regulation

(2010) Sihao Liu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Potential remains for PPAR-targeted drugs

(2010) Dan Jones   NATURE REVIEWS DRUG DISCOVERY

Lipid accumulation in hepatocytes induces fibrogenic activation of hepatic stellate cells

(2009) Hella Wobser et al.   CELL RESEARCH

Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial

(2009) Vlad Ratziu et al.   HEPATOLOGY

PPAR-α and PPAR-γ agonists for type 2 diabetes

(2009) Bernard Charbonnel   LANCET

Rosiglitazone for Nonalcoholic Steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) Trial

(2008) Vlad Ratziu et al.   GASTROENTEROLOGY